Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma

Incomplete surgery of solid tumors is a risk factor for primary treatment failure. Here, we have investigated whether chimeric antigen receptor T cells (CARTs) could be used as an adjuvant therapy to clear residual cancer cells. We tested the feasibility of this approach in two partial resection xen...

Descripción completa

Detalles Bibliográficos
Autores principales: Uslu, Ugur, Da, Tong, Assenmacher, Charles-Antoine, Scholler, John, Young, Regina M., Tchou, Julia, June, Carl H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833675/
https://www.ncbi.nlm.nih.gov/pubmed/36630514
http://dx.doi.org/10.1126/sciadv.ade2526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833675/
https://www.ncbi.nlm.nih.gov/pubmed/36630514
http://dx.doi.org/10.1126/sciadv.ade2526

Ejemplares similares